Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
AL amyloidosis
Mortality
Predictive biomarkers
Prognosis
Staging score
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
revised:
11
12
2023
received:
18
07
2023
accepted:
20
12
2023
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage. This prospective, observational, cohort study included de novo, confirmed cardiac AL amyloidosis patients at the Henri Mondor National Reference Centre. The goal was to identify predictors of mortality to enhance prognostic stratification and improve informed decision-making regarding therapy. Over the 12-year study period, among the 233 patients included, 133 were NYHA III-IV and 179 Mayo 2004 III. The independent predictors for mortality identified were hsTnT, NT-proBNP, cardiac output, and conjugated bilirubin. A novel prognostic, conditional stratification, Mondor amyloidosis cardiac staging (MACS) was developed with biomarker cut-off values for Stage 1: hsTnT ≤ 107 ng/L and NT-proBNP ≤ 3867 ng/L (n = 77; 33%); for stage 2 NT-proBNP > 3867 ng/L (n = 72; 30%). For stage 3, if troponin >107 ng/L, regardless of NT-proBNP then CB 4 μmol/L, was added (n = 41; 17.5%) and stage 4: CB > 4 μmol/L (n = 43; 18.5%). The median overall survival was 8 months 95% CI [2-24]. At 1 year, 102 (44%) patients died and the Kaplan-Meier median survival with MACS Stage 1 was not reached, while stage 2 was 15.2 months (95% CI [11-18]) and stage 3, 6.6 months (95% CI [1-13]). Notably, among European stage II patients, 17.1%, n = 8 were MACS stage 3 and European stage IIIb 21.4% (n = 23) were MACS stage 4. Importantly, among European stage IIIb patients 42.2% (n = 29) were classified MACS stage 4 and 12.5% n = 9 were only MACS stage 2. The Mondor prognostic staging system, including conjugate bilirubin may significantly improve prognostic stratification for patients with severe cardiac amyloidosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
Aurich M, Bucur J, Vey JA, Greiner S, Aus dem Siepen F, Hegenbart U, et al. Prognosis of light chain amyloidosis: A multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy. Open. Heart 2023;10:e002310. doi:10.1136/openhrt-2023-002310
Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-1010. doi:10.1161/01.RES.0000126569.75419.74
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 2010;116:5126-5129. doi:10.1182/blood-2010-06-290668
Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 2017;130:625-631. doi:10.1182/blood-2017-02-767467
Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: A 40-year longitudinal natural history study. Blood Cancer J 2021;11:139. doi:10.1038/s41408-021-00529-w
Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, et al. Ten-year survivors in AL amyloidosis: Characteristics and treatment pattern. Br J Haematol 2019;187:588-594. doi:10.1111/bjh.16096
Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019;133:215-223. doi:10.1182/blood-2018-06-858951
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325-2332. doi:10.1182/blood-2014-04-570010
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-3427. doi:10.1182/blood-2012-12-473066
Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-4324. doi:10.1200/JCO.2013.50.8499
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995. doi:10.1200/JCO.2011.38.5724
Bezard M, Oghina S, Vitiello D, Kharoubi M, Kordeli E, Galat A, et al. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS ONE 2021;16:e0257189. doi:10.1371/journal.pone.0257189
Béquignon E, Guellich A, Bartier S, Raynal M, Prulière-Escabasse V, Canouï-Poitrine F, et al. How your ears can tell what is hidden in your heart: Wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study. Amyloid 2017;24:96-100. doi:10.1080/13506129.2017.1330744
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the american society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr 2017;30:303-371. doi:10.1016/j.echo.2017.01.007
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-271. doi:10.1093/ehjci/jev014
Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, et al. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: Comparison of Freelite and N Latex FLC assays. Clin Chem Lab Med 2017;55:1734-1743. doi:10.1515/cclm-2016-1024
Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 2006;15:651-674. doi:10.1198/106186006X133933
Bak M, Kim D, Choi JO, Kim K, Kim SJ, Jeon ES. Prognostic implication of longitudinal changes of left ventricular global strain after chemotherapy in cardiac light chain amyloidosis. Front Cardiovasc Med 2022;9:904878. doi:10.3389/fcvm.2022.1001753
Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, et al. Prognosis of light chain amyloidosis with preserved LVEF: Added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging 2017;10:398-407. doi:10.1016/j.jcmg.2016.04.008
Slivnick J, Zareba KM, Varghese J, Truong V, Wallner AL, Tong MS, et al. Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis. Open Heart 2022;9:e001808. doi:10.1136/openhrt-2021-001808
Xu J, Qiu Z, Yan M, Wang B, Song Z, Liu H, et al. Prognostic factors of AL-PCMM and AL-MM: A single-center retrospective study. Int J Med Sci 2022;19:588-595. doi:10.7150/ijms.61712
Zhang L-l, Shen K-n, Zhang C-l, Qiu Y, Miao H-l, Feng J, et al. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. Leuk Res 2019;86:106226. doi:10.1016/j.leukres.2019.106226
Dittrich T, Kimmich C, Hegenbart U, Schonland SO. Prognosis and staging of AL amyloidosis. Acta Haematol 2020;143:388-400. doi:10.1159/000508287
Al Saleh AS, Parmar HV, Vaxman I, Visram A, Hasib Sidiqi M, Muchtar E, et al. Prognostic value of NT-proBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplant 2021;56:274-277. doi:10.1038/s41409-020-0990-6
Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart 2014;100:383-388. doi:10.1136/heartjnl-2013-304957
Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116:2455-2461. doi:10.1182/blood-2010-02-267708
Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, et al. Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. Am J Cardiol 2012;110:1180-1184. doi:10.1016/j.amjcard.2012.05.061
Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005;96:982-984. doi:10.1016/j.amjcard.2005.05.057
Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;116:3426-3430. doi:10.1182/blood-2010-05-286567
Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 2019;9:8552. doi:10.1038/s41598-019-44912-x
Velthuis HT, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC - New monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323-1332. doi:10.1515/CCLM.2011.624
Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008;111:4700-4705. doi:10.1182/blood-2007-11-122101
Mahmood S, Wassef NL, Salter SJ, Sachchithanantham S, Lane T, Foard D, et al. Comparison of free light chain assays: Freelite and N Latex in diagnosis, monitoring, and predicting survival in light chain amyloidosis. Am J Clin Pathol 2016;146:78-85. doi:10.1093/ajcp/aqw079
Henriot B, Rouger E, Rousseau C, Escoffre M, Sébillot M, Bendavid C, et al. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. Clin Chem Lab Med 2019;57:1397-1405. doi:10.1515/cclm-2018-1369